Controversies Challenges Consensus
}

Intra-arterial calcification poses “one of the biggest challenges” for endovascular therapy

2019-09-06T16:03:07+01:00

Andrew Holden (Auckland, New Zealand) provides perspective on the first results from the Disrupt PAD III observational registry that were presented at the Charing Cross International Symposium 2019. This large registry is designed to evaluate the use of Intravascular Lithotripsy (IVL; Shockwave) in the treatment of calcified arteries beyond the […]

Intra-arterial calcification poses “one of the biggest challenges” for endovascular therapy2019-09-06T16:03:07+01:00

Highlights from the CX 2019 session, Paclitaxel: The last word

2019-09-06T16:04:24+01:00

The 2019 Charing Cross Symposium (CX; 15–18 April, London, UK) featured an in-depth highlight session on the paclitaxel controversy. […]

Highlights from the CX 2019 session, Paclitaxel: The last word2019-09-06T16:04:24+01:00

With CoveredSeal, Valiant Navion™ offers physicians the “best of both worlds” for TEVAR procedures

2019-09-06T16:05:44+01:00

Paul Hayes (Cambridge, UK), Frank Arko (Charlotte, USA) and Fabio Verzini (Turin, Italy) discuss the Valiant Navion™ (Medtronic) live thoracic endovascular aortic repair (TEVAR) case at Charing Cross 2019, which demonstrated the use of the new CoveredSeal proximal configuration.

Hayes talks about the accuracy of the device’s deployment around the thoracic […]

With CoveredSeal, Valiant Navion™ offers physicians the “best of both worlds” for TEVAR procedures2019-09-06T16:05:44+01:00

Comprehensive innovation programme gives insights into the technologies of the future

2019-09-26T15:00:31+01:00

The CX Innovation Programme showcased technological developments happening in all areas of the Charing Cross Symposium: acute stroke, aortic, peripheral, venous, vascular access, and wound care. Additionally, a new “Dragons’ Den” winner was crowned.

In the first talk of the session, Lindsay Machan (Vancouver, Canada) talked about the lessons he had learnt from being a founder […]

Comprehensive innovation programme gives insights into the technologies of the future2019-09-26T15:00:31+01:00

New MIMICS-2 trial data show helical stents provide durable treatment of diseased femoropopliteal arteries

2019-09-06T16:12:16+01:00

New data from the MIMICS-2 trial show the BioMimics 3D stent, which mimics natural vascular curvature, remains safe and effective for patients with symptomatic atherosclerotic disease of the femoropopliteal arteries two years after implantation.

Principal investigator Timothy Sullivan (Minnesota, USA) presented the two-year findings at this year’s Charing […]

New MIMICS-2 trial data show helical stents provide durable treatment of diseased femoropopliteal arteries2019-09-06T16:12:16+01:00

Endovascular repair matches open surgery for treatment of men with complex but low-risk aortoiliac disease using self-expanding covered stents

2019-04-18T17:16:33+01:00

Michele Antonello

Endovascular repair shortens hospital stay and has comparable outcomes to open surgery when balloon-expandable covered stents are used to treat low-risk male patients with complex aortoiliac lesions, new data show. Michele Antonello (Padua, Italy), described some of the study’s key results during a presentation at […]

Endovascular repair matches open surgery for treatment of men with complex but low-risk aortoiliac disease using self-expanding covered stents2019-04-18T17:16:33+01:00

0.018-inch drug delivery platforms are as effective as 0.035-inch devices

2019-09-06T16:14:14+01:00

Andrew Holden

Interventionists can confidently use lower profile drug delivery platforms, based on data that shows 0.018-inch guidewire devices are non-inferior to 0.035-inch guidewires. In a Podium 1st presentation at Charing Cross (CX) Symposium on Thursday, Andrew Holden (Auckland, New Zealand) said: “At 90 days, we can […]

0.018-inch drug delivery platforms are as effective as 0.035-inch devices2019-09-06T16:14:14+01:00

Endoanchors add to therapy options for AAA

2019-04-18T10:09:07+01:00

Frank Arko

Using EndoAnchors to fix and seal endovascular aortic grafts is safe and effective for short-neck abdominal aortic aneurysm (AAA) patients, two-year data from the ANCHOR global registry have shown. Frank Arko (Charlotte, USA) presented the findings yesterday at CX Symposium in a podium first session, […]

Endoanchors add to therapy options for AAA2019-04-18T10:09:07+01:00

The impact of paclitaxel concerns on vascular access

2019-04-18T10:32:43+01:00

paclitaxel

As part of Wednesday’s CX Vascular Access Workshop in the Pillar Hall Learning Centre, there was a section of the programme on drug-coated balloon trial updates which ended with a panel discussion on whether peripheral vascular disease data is applicable to vascular access. The discussion […]

The impact of paclitaxel concerns on vascular access2019-04-18T10:32:43+01:00

EVAR with an iliac branch endoprothesis is safe and effective

2019-09-06T16:20:32+01:00

Fabio Verzini

Yesterday, during the Aortic Podium 1st session, Fabio Verzini (Turin, Italy) reported that endovascular aneurysm repair (EVAR) with an iliac branch endoprothesis (Gore) is safe and effective. He added that the procedure was associated with improved quality of life in the short term and […]

EVAR with an iliac branch endoprothesis is safe and effective2019-09-06T16:20:32+01:00

Virtual reality stimulates discussion at CX

2019-04-18T10:30:36+01:00

virtual reality

For the first time, the Charing Cross (CX) audience has been able to experience an array of virtual reality live cases in both the peripheral and aortic programmes. The virtual reality live streaming in 360° video, accompanied by a running commentary by the operator, provided a […]

Virtual reality stimulates discussion at CX2019-04-18T10:30:36+01:00

EVAR funding threatened, while strategy for safe, cost-effective repair is “just around the corner”

2019-04-18T09:59:05+01:00

The durability of endovascular aneurysm repair (EVAR) is in the limelight as the UK vascular community awaits the final aortic aneurysm guidelines from the National Institute for Health and Care Excellence (NICE), set to go against widespread endovascular practice in recommending open repair over EVAR. In May […]

EVAR funding threatened, while strategy for safe, cost-effective repair is “just around the corner”2019-04-18T09:59:05+01:00

Vascular recruitment a “universal problem”: The global perspective

2019-04-18T10:04:27+01:00

Sophie Renton

Across the globe, vascular recruitment is struggling. This was the reason why delegates convened in the Upper Auditorium yesterday afternoon for a CX Highlight Session dedicated to the topic, where representatives from three continents explained exactly how and why the vascular specialty is experiencing this […]

Vascular recruitment a “universal problem”: The global perspective2019-04-18T10:04:27+01:00

“Urgent action is required for patients with venous ulceration”

2019-04-16T21:56:16+01:00

Alun Davies

Despite what current guidelines denote in addition to the emergence of data supporting the early intervention of venous ulceration, Alun Davies (London, UK) put forward that the recommendations are consistently being ignored, and highlighted that: “Urgent action is required to improve referral pathways between primary […]

“Urgent action is required for patients with venous ulceration”2019-04-16T21:56:16+01:00

CX Special Session will discuss the use of paclitaxel devices

2019-09-06T16:37:19+01:00

CX Executive Board Members Gunnar Tepe and Thomas Zeller introduce the CX Special Session which aims to give the last word on paclitaxel and work with the vascular community to find the way forward.

Watch the video below, and see the final CX 2019 programme here.

[…]

CX Special Session will discuss the use of paclitaxel devices2019-09-06T16:37:19+01:00

CX 2019: The last word on the paclitaxel controversy

2019-02-07T17:15:34+00:00

Since the publication of Katsanos et al’s meta-analysis in the Journal of the American Heart Association (JAHA), the science and support for paclitaxel-releasing devices in the legs is an unfolding story.

A CX 2019 Highlight session will feature two hours of independent review of the data and in-depth debate and discussion.

CX […]

CX 2019: The last word on the paclitaxel controversy2019-02-07T17:15:34+00:00

CX 2020 Abstracts

2019-11-22T13:30:34+00:00

Abstract Submissions for CX 2020 are now closed

The CX Abstract Board is calling for senior and trainee doctors in the vascular and endovascular field to submit their abstracts for presentation at the Charing Cross Symposium (21–24 April 2020, London, UK).

The best abstract presentation […]

CX 2020 Abstracts2019-11-22T13:30:34+00:00
Go to Top